Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
:6MK
6MK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€67.20 - €125.60
Previous CloseN/A
Volume75.00
Average Volume (3M)3.86K
Market Cap
€170.43B
Enterprise Value€276.94B
Total Cash (Recent Filing)$8.24B
Total Debt (Recent Filing)$19.10B
Price to Earnings (P/E)11.1
Beta0.32
Next Earnings
Apr 24, 2025EPS Estimate
1.86Last Dividend Ex-Date
Mar 17, 2025Dividend Yield4.05%
Share Statistics
EPS (TTM)6.23
Shares Outstanding2,516,394,000
10 Day Avg. Volume5,103
30 Day Avg. Volume3,857
Financial Highlights & Ratios
PEG Ratio0.00259
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)17.00
P/FCF Ratio17.00
Enterprise Value/Market Cap1.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.34
Enterprise Value/Ebitda10.28
Forecast
1Y Price Target
€93.96Price Target Upside36.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Animal Health BusinessInvestors should be applying a higher multiple to stable revenue streams like the Animal Health business, which has no policy-related risk.
Phase 3 TrialsThe conditions are in place for a stock recovery as focus shifts to execution on Winrevair and upcoming data from three ongoing Phase 3 trials for its oral PCSK9 program.
Bears Say
Physician CautionUse in lower-risk PAH patients is still limited by physician caution regarding bleeding risk.
Vaccine UncertaintyA significant degree of vaccine-related uncertainty is already reflected in MRK shares, which could make the stock disproportionately sensitive to updates from other parts of the pharma business.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
21.26%
Mutual Funds
1.02% Other Institutional Investors
54.01% Public Companies and
Individual Investors
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €67.20 and its highest was €125.60 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is €170.43B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Apr 24, 2025 which is tomorrow.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Feb 04, 2025. The company reported €1.512 earnings per share for the quarter, beating the consensus estimate of €1.415 by €0.098.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €2.747 which represents an annual dividend yield of 4.05%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.86.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,516,394,000 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.512 in its last earnings report, beating expectations of €1.415. Following the earnings report the stock price went down -10.822%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
---
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€93.96 (36.37% Upside)
€93.96 (36.37% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $141.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.27%
12-Months-Change
Fundamentals
Return on Equity
40.81%
Trailing 12-Months
Asset Growth
9.78%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
---
6MK Company Deck
---
6MK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with strong performance in key areas like oncology and new product launches, but challenges persist with GARDASIL in China and impacts from Medicare Part D redesign. Although the company remains confident in its long-term growth potential, short-term headwinds are acknowledged.Read More>---
6MK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
---
6MK Stock 12 Month Forecast
Average Price Target
€93.96
▲(36.37% Upside)
Technical Analysis
Best Analysts Covering 6MK
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+4.14%
reiterated a buy rating 22 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +4.14% per trade.
---